Anne Rowe
Authored Items
By Anne Rowe
March 2023 Vol 16, No 2
An analysis from the ARASENS trial showed that the addition of darolutamide (Nubeqa) to androgen-deprivation therapy (ADT) and docetaxel significantly improved overall survival (OS) in subgroups of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with high-volume and high-risk disease and should be considered the new standard of care for this patient population. Read More ›
By Anne Rowe
TOP - October 2021 Vol 14, No 6 | Biosimilars
The advent of biologic drugs has had a significant impact on the management of patients with cancer. However, the high costs associated with these agents can hinder treatment access for many patients and place a significant burden on healthcare systems. Read More ›
By Anne Rowe
TOP - October 2021 Vol 14, No 6 | Biosimilars
Results from a phase 3 clinical trial showed equivalence between the bevacizumab biosimilar, BCD-021, and the reference product, bevacizumab (Avastin), in terms of overall response rate (ORR) in patients with stage IIIB or IV nonsquamous non–small-cell lung cancer. Read More ›